Retatrutide
An investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors. Regulates appetite, increases energy expenditure, and improves metabolic function for extreme weight loss.
Key Benefits for Med Spas
Clinical Evidence
"Phase 2 trial: up to 24.2% weight loss at 48 weeks. Phase 3: 28.7% at 68 weeks."
Administration
Available Options
Wholesale pricing. Contact us for volume discounts and custom orders.
Quick Facts
Related Products
View allSemaglutide
A GLP-1 receptor agonist that mimics the naturally occurring GLP-1 hormone. Stimulates insulin secretion, suppresses appetite, and slows gastric emptying for powerful weight management.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that activates both incretin receptors for superior weight loss. Regulates blood sugar, suppresses appetite, and increases feelings of fullness.
AOD-9604
A modified fragment of human growth hormone that isolates fat-burning properties. Stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth.